These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35403160)

  • 1. Absolute Lymphocyte Count, Platelet-to-Lymphocyte Ratio, and Overall Survival in Eribulin-treated HER2-negative Metastatic Breast Cancer Patients.
    Koyama Y; Kawai S; Uenaka N; Okazaki M; Asaoka M; Teraoka S; Ueda AI; Miyahara K; Kawate T; Kaise H; Yamada K; Ishikawa T
    Cancer Diagn Progn; 2021; 1(5):435-441. PubMed ID: 35403160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
    Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
    BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study.
    Ueno A; Maeda R; Kin T; Ito M; Kawasaki K; Ohtani S
    Chemotherapy; 2019; 64(5-6):259-269. PubMed ID: 32305977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
    Kanaoka H; Nagahashi M; Atake Y; Hattori A; Bun A; Fukui R; Ozawa H; Fujimoto Y; Higuchi T; Natori K; Imamura M; Murase K; Takatsuka Y; Miyoshi Y
    Anticancer Res; 2022 Oct; 42(10):4867-4878. PubMed ID: 36192009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
    Goto W; Kashiwagi S; Takada K; Asano Y; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
    Anticancer Res; 2022 Feb; 42(2):939-946. PubMed ID: 35093893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive prognostic prediction of metastatic breast cancer treated with eribulin using blood‑based parameters and ratio.
    Shimada H; Fujimoto A; Matsuura K; Kohyama S; Nukui A; Ichinose Y; Asano A; Ohara M; Ishiguro H; Osaki A; Saeki T
    Mol Clin Oncol; 2024 Feb; 20(2):15. PubMed ID: 38274088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin.
    Su MX; Lin HW; Nguyen HTH; Lin TC; Chen CJ; Wang HC; Wu CT; Wu YC; He GY; Liu LC; Huang CH
    BMC Cancer; 2024 Feb; 24(1):195. PubMed ID: 38347468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types.
    Morisaki T; Kashiwagi S; Asano Y; Goto W; Takada K; Ishihara S; Shibutani M; Tanaka H; Hirakawa K; Ohira M
    World J Surg Oncol; 2021 Nov; 19(1):324. PubMed ID: 34775950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan.
    Takahashi M; Inoue K; Mukai H; Yamanaka T; Egawa C; Miyoshi Y; Sakata Y; Muramoto K; Ikezawa H; Matsuoka T; Tsurutani J
    Breast Cancer; 2021 Jul; 28(4):945-955. PubMed ID: 33677779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.
    Watanabe J; Saito M; Horimoto Y; Nakamoto S
    Breast Cancer Res Treat; 2020 May; 181(1):211-220. PubMed ID: 32249370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.
    Miyoshi Y; Yoshimura Y; Saito K; Muramoto K; Sugawara M; Alexis K; Nomoto K; Nakamura S; Saeki T; Watanabe J; Perez-Garcia JM; Cortes J
    Breast Cancer; 2020 Jul; 27(4):706-715. PubMed ID: 32133606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin.
    Sata A; Fukui R; Miyagawa Y; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Imamura M; Miyoshi Y
    Anticancer Res; 2020 Jul; 40(7):4147-4156. PubMed ID: 32620664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between platelet-to-lymphocyte ratio and outcomes in HER2-positive advanced breast cancer patients treated with pyrotinib: a retrospective study.
    Hao L; Dong J; Yu H; Chen J; Han X; Pan Y
    Transl Cancer Res; 2023 Oct; 12(10):2726-2741. PubMed ID: 37969380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial.
    Tokunaga E; Miyoshi Y; Dozono K; Kawaguchi T; Toi M
    Oncologist; 2024 Mar; 29(3):e319-e329. PubMed ID: 37971418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Metastatic Colorectal Cancer.
    Bulut G; Ozdemir ZN
    J Gastrointest Cancer; 2022 Mar; 53(1):1-6. PubMed ID: 33686459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absolute lymphocyte count and C-reactive protein-albumin ratio can predict prognosis and adverse events in patients with recurrent esophageal cancer treated with nivolumab therapy.
    Inoue H; Shiozaki A; Fujiwara H; Konishi H; Kiuchi J; Ohashi T; Shimizu H; Arita T; Yamamoto Y; Morimura R; Kuriu Y; Ikoma H; Kubota T; Okamoto K; Otsuji E
    Oncol Lett; 2022 Aug; 24(2):257. PubMed ID: 35765281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.
    Huszno J; Kolosza Z; Mrochem-Kwarciak J; Rutkowski T; Skladowski K
    Oncology; 2019; 97(1):7-17. PubMed ID: 31048577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
    Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.